Efficacy Study of Crizotinib in East Asian Patients With ROS1-Positive, ALK-Negative Advanced NSCLC

Phase-2, Open-Label, Single-Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients with Advanced ALK-Negative Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the C-ROS Oncogene (ROS1) Locus

Category & Conditions:
Cancer
Medicine:
XALKORI®(CRIZOTINIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
A8081063
Open Plain Language Summary Result:Click here